• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

AM - 251和SR144528是酰基辅酶A:胆固醇酰基转移酶抑制剂。

AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors.

作者信息

Thewke Douglas, Freeman-Anderson Natalie, Pickle Theresa, Netherland Courtney, Chilton Courtney

机构信息

Department of Biochemistry and Molecular Biology, Quillen College of Medicine, East Tennessee State University, 807 University Parkway, Johnson City, TN 37614, USA.

出版信息

Biochem Biophys Res Commun. 2009 Apr 3;381(2):181-6. doi: 10.1016/j.bbrc.2009.02.020. Epub 2009 Feb 11.

DOI:10.1016/j.bbrc.2009.02.020
PMID:19338772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2665256/
Abstract

Oxysterol-induced macrophage apoptosis may have a role in atherosclerosis. Macrophages lacking the type 2 cannabinoid receptor (CB2) are partially resistant to apoptosis induced by 7-ketocholesterol (7KC). AM-251 and SR144528 are selective antagonists of CB1 and CB2 receptors, respectively. We observed that both compounds reduce 7KC-induced apoptosis in Raw 264.7 macrophages. As oxysterol-induced macrophage apoptosis requires acyl-coenzymeA:cholesterol acyltransferase (ACAT) activity, we tested their affects on ACAT activity. AM-251 and SR144528 both reduced cholesteryl ester synthesis in unstimulated and acetylated LDL-stimulated Raw 264.7 macrophages, CB2(+/+) and CB2(-/-) peritoneal macrophages, as well as in vitro, in mouse liver microsomes. Consistent with inhibition of ACAT, the development of foam cell characteristics in macrophages by treatment with acetylated LDL was reduced by both compounds. This work is the first evidence that AM-251 and SR144528 are inhibitors of ACAT and as a result, might have anti-atherosclerotic activities independent of their affect on cannabinoid signaling.

摘要

氧化甾醇诱导的巨噬细胞凋亡可能在动脉粥样硬化中起作用。缺乏2型大麻素受体(CB2)的巨噬细胞对7-酮胆固醇(7KC)诱导的凋亡具有部分抗性。AM-251和SR144528分别是CB1和CB2受体的选择性拮抗剂。我们观察到这两种化合物均可减少Raw 264.7巨噬细胞中7KC诱导的凋亡。由于氧化甾醇诱导的巨噬细胞凋亡需要酰基辅酶A:胆固醇酰基转移酶(ACAT)活性,我们测试了它们对ACAT活性的影响。AM-251和SR144528均可降低未刺激和乙酰化低密度脂蛋白刺激的Raw 264.7巨噬细胞、CB2(+/+)和CB2(-/-)腹膜巨噬细胞以及体外小鼠肝微粒体中的胆固醇酯合成。与ACAT的抑制作用一致,两种化合物均减少了用乙酰化低密度脂蛋白处理巨噬细胞后泡沫细胞特征的发展。这项工作首次证明AM-251和SR144528是ACAT的抑制剂,因此可能具有独立于其对大麻素信号传导影响的抗动脉粥样硬化活性。

相似文献

1
AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors.AM - 251和SR144528是酰基辅酶A:胆固醇酰基转移酶抑制剂。
Biochem Biophys Res Commun. 2009 Apr 3;381(2):181-6. doi: 10.1016/j.bbrc.2009.02.020. Epub 2009 Feb 11.
2
Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.利莫那班是酰基辅酶 A:胆固醇酰基转移酶 1 和 2 的双重抑制剂。
Biochem Biophys Res Commun. 2010 Aug 6;398(4):671-6. doi: 10.1016/j.bbrc.2010.06.134. Epub 2010 Jul 6.
3
Acyl-coenzyme A:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages.酰基辅酶A:胆固醇酰基转移酶促进氧化型低密度脂蛋白/氧化甾醇诱导的巨噬细胞凋亡。
J Lipid Res. 2005 Sep;46(9):1933-43. doi: 10.1194/jlr.M500101-JLR200. Epub 2005 Jul 1.
4
Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes.巨噬细胞泡沫细胞中胆固醇和氧化甾醇的代谢及亚细胞分布。氧化酯在溶酶体中的积累。
J Lipid Res. 2000 Feb;41(2):226-37.
5
Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.对巨噬细胞ACAT的选择性药理抑制会增加动脉粥样硬化小鼠和兔模型中的斑块形成。
Atherosclerosis. 2001 Apr;155(2):359-70. doi: 10.1016/s0021-9150(00)00599-2.
6
Inhibitory effect of a new ureidophenol derivative T-2591 on LDL oxidation and ACAT activity.新型脲基酚衍生物T-2591对低密度脂蛋白氧化及酰基辅酶A:胆固醇酰基转移酶活性的抑制作用。
Biol Pharm Bull. 1997 Oct;20(10):1056-60. doi: 10.1248/bpb.20.1056.
7
Effect of the ACAT inhibitor, HL-004, on cholesterol metabolism in macrophages.ACAT抑制剂HL-004对巨噬细胞胆固醇代谢的影响。
Cell Mol Biol (Noisy-le-grand). 1996 Sep;42(6):865-72.
8
Protein synthesis inhibition in mouse peritoneal macrophages results in increased acyl coenzyme A:cholesterol acyl transferase activity and cholesteryl ester accumulation in the presence of native low density lipoprotein.在天然低密度脂蛋白存在的情况下,小鼠腹腔巨噬细胞中的蛋白质合成抑制会导致酰基辅酶A:胆固醇酰基转移酶活性增加和胆固醇酯积累。
J Biol Chem. 1987 Sep 5;262(25):12175-81.
9
Effect of SMP-500, a novel acyl-coA:cholesterol acyltransferase inhibitor, on the cholesterol esterification and its hypocholesterolemic properties.新型酰基辅酶A:胆固醇酰基转移酶抑制剂SMP - 500对胆固醇酯化作用及其降胆固醇特性的影响。
Pharmacology. 2002 May;65(1):18-25. doi: 10.1159/000056181.
10
Effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase inhibitor, on cholesterol esterification and high-density lipoprotein-induced cholesterol efflux in macrophages.新型酰基辅酶A:胆固醇酰基转移酶抑制剂NTE-122对巨噬细胞中胆固醇酯化及高密度脂蛋白诱导的胆固醇外流的影响
Jpn J Pharmacol. 1999 Feb;79(2):159-67. doi: 10.1254/jjp.79.159.

引用本文的文献

1
Pharmacological blockade of cannabinoid receptor 2 signaling does not affect LPS/IFN-γ-induced microglial activation.药理学阻断大麻素受体 2 信号通路不影响 LPS/IFN-γ 诱导的小胶质细胞活化。
Sci Rep. 2023 Jul 10;13(1):11105. doi: 10.1038/s41598-023-37702-z.
2
The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.内源性大麻素系统与心脏病:2型大麻素受体的作用
Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34-51. doi: 10.2174/1871529X18666180206161457.
3
Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.

本文引用的文献

1
Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.利莫那班是一种选择性大麻素CB1受体拮抗剂,可抑制低密度脂蛋白受体缺陷小鼠的动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):12-8. doi: 10.1161/ATVBAHA.108.168757. Epub 2008 Oct 9.
2
Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis.大麻素(CB2)受体缺陷降低了巨噬细胞对氧化型低密度脂蛋白/氧化甾醇诱导的细胞凋亡的易感性。
J Lipid Res. 2008 Nov;49(11):2338-46. doi: 10.1194/jlr.M800105-JLR200. Epub 2008 Jul 9.
3
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
利莫那班是酰基辅酶 A:胆固醇酰基转移酶 1 和 2 的双重抑制剂。
Biochem Biophys Res Commun. 2010 Aug 6;398(4):671-6. doi: 10.1016/j.bbrc.2010.06.134. Epub 2010 Jul 6.
利莫那班对腹型肥胖合并冠状动脉疾病患者动脉粥样硬化进展的影响:STRADIVARIUS随机对照试验
JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.
4
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.内源性大麻素阻断剂用于改善2型糖尿病患者的血糖控制和血脂水平
Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S29-32. doi: 10.1016/j.amjmed.2006.11.014.
5
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].利莫那班改善肥胖或超重受试者的心血管代谢风险状况:RIO研究综述
Rev Med Suisse. 2006 Aug 23;2(76):1916-23.
6
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.大麻素-1受体阻滞剂利莫那班对超重或肥胖患者体重及心血管代谢危险因素的影响:北美RIO研究:一项随机对照试验。
JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761.
7
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.利莫那班对血脂异常超重患者代谢危险因素的影响。
N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537.
8
A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development.凋亡抑制因子AIM/Spalpha/Api6在动脉粥样硬化发展中的作用。
Cell Metab. 2005 Mar;1(3):201-13. doi: 10.1016/j.cmet.2005.02.002.
9
Acyl-coenzyme A:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages.酰基辅酶A:胆固醇酰基转移酶促进氧化型低密度脂蛋白/氧化甾醇诱导的巨噬细胞凋亡。
J Lipid Res. 2005 Sep;46(9):1933-43. doi: 10.1194/jlr.M500101-JLR200. Epub 2005 Jul 1.
10
Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis.专题综述系列:免疫系统与动脉粥样硬化。调节单核细胞在动脉粥样硬化中募集的分子机制。
J Lipid Res. 2005 Aug;46(8):1582-90. doi: 10.1194/jlr.R500008-JLR200. Epub 2005 Jun 16.